Shape-shifting mirrors on NASA’s new space telescope could unveil Jupiters like our own

When NASA’s Nancy Grace Roman Space Telescope launches, as early as the end of next month, it will attempt one of astronomy’s most precise disappearing acts to date. The telescope will carry the first space-bound “active” coronagraph, an instrument that effectively erases most of the light from a star during photography.

It will allow astronomers to take the first pictures of planets orbiting other stars that are similar to those in our solar system. Ultimately, it could pave the way for a future mission that could snap the first photos of Earth-like worlds.

“I hope it’s remembered for it being that critical stepping stone for … finding Earth 2.0,” says Brandon Creager, the instrument’s lead mechanical engineer at NASA’s Jet Propulsion Laboratory (JPL).

Named after Nancy Grace Roman, NASA’s first chief of astronomy, this new telescope will carry a roughly 300-megapixel wide-field camera that will enable it to capture images about 100 times larger than the Hubble Space Telescope’s widest exposures at a similar resolution.

These capabilities will help astronomers unpack the mysterious identities of dark matter and dark energy—and to detect around 100,000 new exoplanets, planets outside our solar system, whose presence can be inferred from the way they distort the starlight of more distant stars. Javier Viaña, a research scientist at Harvard who has had two projects selected for Roman’s highly competitive first year of observing, compares the leap to moving from “interviewing a handful of people” to “conducting a global census.”

Another camera will use the coronagraph, blocking out a star’s light as it observes one stellar system at a time. The instrument will allow astronomers an unprecedented look at the space around stars, enabling them to see smaller, dimmer, and more close-in exoplanets. “It’s giving us the ability to see planets that we haven’t been able to physically see before,” says Creager.

The anatomy of a vanishing trick

Coronagraphs in space aren’t new. But earlier incarnations, such as those currently aboard Hubble and the James Webb Space Telescope, use a stationary system to block a star’s blinding light. The approach does help, but it’s a bit like putting your thumb over a flashlight while searching a dark room for a firefly. Though the bulb vanishes, stray glare can still escape and overwhelm the light of the insect. Inside a telescope, that glare can come from light leaking around the edges of machinery or from minuscule imperfections in mirrors and coatings that can scatter starlight into speckles. All this can hide, or even impersonate, a planet.

Roman’s coronagraph, however, will attempt something completely unseen in space telescopes until this year: Before each observation, it will measure that leftover light and try to suppress it, a technique known as active wavefront control.

The telescope is able to do this because it contains two deformable mirrors. Each has a 48-by-48 checkerboard of actuators (tiny pistons) beneath a thin, deformable sheet of glass. Applying a small amount of voltage makes the actuators contract and tug their patches of mirror slightly backward, like thousands of microscopic fingers delicately sculpting a surface.

The effect is very subtle: Each patch of mirror can deform by up to 0.5 micrometers, or about one-fourth the size of an E. coli bacterium, and in increments as small as approximately 10 picometers. That’s about a tenth the diameter of a hydrogen atom, says Ilya Poberezhskiy, the instrument’s project systems engineer at JPL.

The actuators allow the mirrors to create an “active wavefront,” where each component is moved to the perfect position to cancel out incoming waves of unwanted light—a bit like a pair of noise-canceling headphones, but for light instead of sound. The “canceled-out” light creates a “doughnut-shaped region around the star where we suppress starlight and where we’re hoping to see exoplanets,” says Poberezhskiy.

Compared with current space-based coronagraphs, the system is expected to improve sensitivity to exoplanets against the glare of their host stars by a factor of up to 1,000, revealing planets that would have been far too faint to detect before.

Like Hubble and JWST, Roman also uses masks, patterned plates placed in the path of the light that are designed to block the photons that run into them. One tool in Roman’s mask arsenal is “silicon grass,” a thicket of microscopic spikes on some masks that can be used in certain configurations to absorb photons so they don’t bounce around the telescope and accidentally reach a detector.

Light entering the forest bounces deeper and deeper between the blades and gets trapped instead of reflecting back toward the camera. “Once the light gets into there, it never gets out,” Poberezhskiy says. The mirrors and masks form a succession of gates and hedges to guide as much of the preserved planetary light as possible toward the final detector.

Alien Jupiters

This elaborate setup could open a new chapter in the direct imaging of exoplanets. Nearly all exoplanets photographed so far are oversize youngsters that are nothing like the residents of our solar system: several times the mass of Jupiter, still glowing with the heat left over from their birth, and orbiting tens or hundreds of times farther from their star than the Earth is from the sun. This is because they are relatively easy to see. Their size, warmth, and distance from their parent star makes them shine brightly in infrared light, far away from the worst of the stellar glare.

Roman, however, could directly image a true Jupiter analogue—a planet similar to Jupiter in mass and circling a sunlike star a few times farther out than Earth is from our sun. Unlike the hot Jupiters we can see now, this one would be a much more mature gas giant like ours, primarily reflecting its parent star’s light after billions of years of cooling instead of heavily emitting its own.

Astronomers have been able to infer the existence of such planets from the gravitational wobble they impart to the star. Roman instead will collect starlight reflected from the planet itself. “We’re not looking at the star. We’re not looking at the effect of the planet on the star,” says Meredith MacGregor, a professor of astronomy at Johns Hopkins who has also secured an observing program. “We are actually looking at the planet, and that is super powerful.”

Once this instrument becomes available, it will become the scientists’ turn to do their jobs. “I’m honestly a little terrified about how we’re all going to deal with it, because I think it’s just so much data,” MacGregor says. “I think people will legitimately still be working on Roman data for decades.”

But don’t expect to see a 4K photo of an alien Jupiter in the coming months. Roman will not be able to resolve such a planet into a solid globe—at best, it will likely resemble a smattering of pixels. Still, that will be enough, MacGregor says, as Roman can then use the coronagraph to get information on the various wavelengths of light from the planet, which can tell astronomers about its atmospheric chemistry.

“You’re taking something that’s a point of light and turning it into an actual world,” she says, “because if you know that about its atmosphere, now you know something about the surface of the planet and the possibility of life being on that planet, right? So that’s a big step.”

During its first observations, scientists and engineers will see whether they can hold a star at the very center of the coronagraph’s masks, shape the mirrors, “dig” the dark doughnut (as Poberezhskiy describes it), and then maintain everything as the spacecraft moves through space and actively changes temperature.

The results will inform NASA’s proposed Habitable Worlds Observatory, the daydream of many an exoplanet astronomer, which will in theory be able to separate the light of an Earthlike planet from that of a sunlike star, over 10 billion times brighter.

Creager, who has worked on the instrument since 2018, is proud of the achievement: “Not too many people get to say, ‘I built something and it’s taking a picture of a planet that’s at a star that’s 50 light-years away or 100 light-years away.’” He imagines the moment he and his team will be able to look at the first image as it arrives: “Yes, we did that.” While the planet may show up only as a tiny dot, Roman’s achievement will be the darkness engineered around it.

Opinion: STAT+: Hospitals’ AI may be drifting. Who’s watching?

Walk into almost any U.S. hospital today and you will find AI doing some of the important work of medicine: drafting clinical notes, flagging sepsis, screening imaging, conducting prior authorizations, and answering patient messages. Adoption is moving fast, and the benefits are real.

But there’s a problem. Most health systems are monitoring the safety and performance of these tools the same way they govern a new MRI scanner in 2010: a subcommittee, a checklist, a quarterly meeting, an approval or a rejection. The process could take six months or longer.

That approach was already strained for older digital tools. For AI, it is dangerously inadequate, and the responsibility for fixing it rests not with IT, but with senior leadership.

Continue to STAT+ to read the full story…

Opinion: STAT+: I’m a cardiologist. I’m not sure the new cholesterol drug enlicitide is a game-changer

A long-awaited moment in preventive cardiology arrived last week, when enlicitide (which Merck is selling under the name Lipfendra) was approved by the FDA to lower blood cholesterol levels.

As the first oral PCSK9 inhibitor — powerful cholesterol-lowering medications, that, until now, have only been injectable — enlicitide itself is an impressive achievement. It punctuates a story of pharmaceutical innovation that has glided from the stories of families enrolled in the Dallas Heart Study at the bedside, to drug targets discovered at the lab bench, all ultimately transforming care back at the bedside.

It also comes at an opportune time. With new clinical guidelines supporting a more aggressive approach to lowering cholesterol levels, enlicitide may be particularly useful for people with either established or at high risk for cardiovascular disease. For the millions of Americans who fit into these groups, it has already been hailed as a game changer. But the story here — of whom it would actually help, and what it implies about prevention today — is more complicated.

Continue to STAT+ to read the full story…

STAT+: Federal health quality research grants worth $109 million ended early

Dozens of researchers funded by the federal Agency for Healthcare Research and Quality received notices last week that they would not receive future installments of funding for their ongoing research grants. While frustrating, the development was largely not a surprise to these researchers, many of whom had been waiting months for renewed funding or been unable to get explanations as to why the funding spigots had run dry from staffers at the agency. 

The notices punctuated nearly a year of uncertainty for health services researchers funded by AHRQ and left those who lost funding concerned about the future of their field. AcademyHealth, a professional organization representing health services researchers, has confirmed at least 78 grants worth $200 million have been affected. In all, those grants had $109.2 million in funding remaining, it  estimated.

Grant recipients were told in a letter of “non-award” that “AHRQ is adjusting its discretionary health services research award portfolio in order to better prioritize agency resources towards the above-mentioned priorities to best serve the interests of the Federal Government,” according to one such letter reviewed by STAT. The letter states the agency is prioritizing research on patient safety, antibiotic resistance, AI, long Covid, nutrition, and understanding autism, among others. 

Continue to STAT+ to read the full story…

UCSD, IGI Partnership Expands CRISPR Innovation Across Health, Agriculture, and the Environment

California may be known as the Golden State, but it may well be referred to as the Genome Editing state after this week’s announcement of an inter-state partnership. The University of California (UC), San Diego, and the Innovative Genomics Institute (IGI), founded by Nobel laureate and CRISPR gene editing co-discoverer Jennifer Doudna, announced a new partnership to jointly develop cutting-edge genomic tools for addressing large-scale challenges in health and the environment.

Doudna founded the IGI in 2015 with the aim of translating the success of gene editing in the lab into practical solutions for large societal problems. Initially formed as a partnership between UC Berkeley and UC San Francisco with a focus on using CRISPR in human health, the IGI expanded to include sustainable agriculture and climate change applications of genome editing, adding UC Davis as a partner. UC San Diego is joining as the IGI’s fourth UC partner campus, combining research strengths in environmental and marine science, engineering and computer science, and biomedical and life sciences to develop the next generation of genome-editing tools and applications.

“I’m thrilled that the IGI is now partnering with UC San Diego,” said Doudna. “The mission of the IGI is to develop solutions that can not only scale to meet the biggest challenges in health and climate, but to make solutions that are accessible to those who need them most. UC San Diego helps us expand that real-world impact.”

jumbo phage
An artistic depiction of a jumbo phage infecting a bacterium.
[Margot Riggi]

The relationship between UC San Diego and IGI research labs has been building over the past decade. For several years, the IGI has been collaborating with UC San Diego researchers Joe Pogliano, PhD, professor in the Department of Molecular Biology, and Kit Pogliano, PhD, dean and professor in the School of Biological Sciences, on applied microbiology projects. They have worked with UC Berkeley-based labs on developing new therapies focusing on “jumbo phage” for antibiotic-resistant bacterial infections as well as a novel defense strategy against viral infections.

In 2023, UC San Diego researchers were awarded $10 million by the Howard Hughes Medical Institute to explore the biomedical promise of jumbo phage as therapeutic agents. Also in 2023, the IGI received a $70 million gift through the Audacious Project to develop microbiome-editing tools and apply them to problems caused by microbes and microbiome imbalances, including livestock methane emissions and inflammatory diseases like asthma. Other areas of the effort focus on developing more efficient tools for genome editing across a wide breadth of microorganisms to expand the impact of this technology.

In the environmental arena, UC San Diego researchers have worked closely with UC Berkeley labs since 2018 to develop tools for combatting crop pests, managing disease-carrying mosquito populations, and developing safe protocols for environmental applications of genomic technologies.

“UC San Diego brings exceptional strengths across biological sciences, medicine, engineering, computation, environmental research, and ocean science that align powerfully with the IGI’s mission,” said Pogliano.

In addition to the current collaborations, IGI’s executive director Brad Ringeisen foresees multiple areas of synergy: “UC San Diego’s strengths in engineering, medical devices, environmental research, and the microbiome complement IGI’s current research areas, and allow us to expand our societal impact in new ways,” he said.

New joint projects of particular interest include interdisciplinary programs designed to bolster the climate resilience of our oceans and soils through innovative scalable solutions, and combining UC Berkeley’s biotechnology discovery engine with UC San Diego’s biomedical research and health system to improve the drug discovery pipeline for rapid translation across areas like antimicrobial resistance and neurodegenerative disease.

The post UCSD, IGI Partnership Expands CRISPR Innovation Across Health, Agriculture, and the Environment appeared first on GEN – Genetic Engineering and Biotechnology News.

Diagnostic Discrimination of BOKE STARS, a Bimodal Continuous Performance Test, for Attention-Deficit/Hyperactivity Disorder Assessment in Chinese Children: Single-Center Case-Control Study

Background: Attention-deficit/hyperactivity disorder (ADHD) affects 6.3% of Chinese children, but only 10% are diagnosed, as diagnosis is hindered by low awareness and lack of culturally adapted, objective tools. Existing continuous performance tests are unimodal and lack validity. Objective: This study aimed to conduct an initial evaluation of the diagnostic discrimination of BOKE STARS (Sustained Task and Attention Response Screening), a culturally adapted bimodal continuous performance test, for distinguishing children with ADHD from typically developing children in a Chinese clinical setting. Methods: In this prospective, single-center diagnostic accuracy study with a case-control design, 100 children aged 6 to 12 years (n=50 with ADHD and n=50 controls) were recruited at Xinhua Hospital between January and May 2024. Parents completed the Swanson, Nolan, and Pelham Rating Scale–fourth version (SNAP-IV), and children completed the BOKE STARS assessment on a tablet device under standardized conditions. Group comparisons were conducted using independent-sample 2-tailed tests or Mann-Whitney tests, as appropriate. Receiver operating characteristic (ROC) curve analysis was performed in the full case-control sample to assess diagnostic discrimination. Sensitivity and specificity were reported descriptively across ROC-derived cutoffs; these cutoffs were not interpreted as clinically validated diagnostic thresholds. Secondary exploratory analyses included comparisons among ADHD subtypes and correlations between BOKE STARS indices and parent-reported SNAP-IV symptom severity scores. Results: Compared with controls, children with ADHD performed significantly worse on all major BOKE STARS indices, including errors of omission, errors of commission, reaction time, reaction time variability (RTV), discrimination prime, and total score. In the full case-control sample, the total score showed the strongest diagnostic discrimination (area under the ROC curve [AUC] 0.962, 95% CI 0.931-0.992), followed by RTV (AUC 0.919, 95% CI 0.867-0.971), errors of omission (AUC 0.884, 95% CI 0.818-0.950), and discrimination prime (AUC 0.819, 95% CI 0.737-0.900). Errors of commission (AUC 0.689, 95% CI 0.585-0.792) and reaction time (AUC 0.634, 95% CI 0.524-0.743) showed comparatively weaker discrimination. No significant differences were observed among ADHD subtypes. Several BOKE STARS indices were modestly correlated with SNAP-IV inattention and hyperactivity or impulsivity scores. Conclusions: BOKE STARS showed promising preliminary diagnostic discrimination for identifying Chinese children with ADHD in this case-control sample, with the total score and RTV showing the strongest discriminatory performance. However, because the case-control design artificially fixed the ratio of ADHD cases to controls, diagnostic performance estimates and exploratory cutoffs should be interpreted cautiously and should not be considered representative of real-world clinical diagnostic performance. BOKE STARS may serve as an adjunctive assessment tool to complement clinical interviews and caregiver-reported rating scales, but further external validation in larger and clinically heterogeneous populations is required before broader clinical implementation.
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/a352c65e649b80c4b66c3ed01598115e" />

Clinical Decision Support for Digital Dietary Counseling Under GLP-1 Receptor Agonist Therapy: Convergent Mixed Methods Usability and Treatment Satisfaction Pilot Study of the Personalized Nutrition Advisor

Background: Dietary counseling is an essential complement to the growing use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to achieve sustainable weight loss. Diverse patient needs, the demand for ongoing support, and limited resources underscore the potential of using digital support tools. Objective: This study aimed to evaluate the usability, treatment satisfaction, and weight effects of a personalized nutrition advisor (PNA), a prototype decision-support tool designed to facilitate personalized weight management counseling. Methods: We assessed usability, treatment satisfaction, and weight effects of a web-based PNA prototype dashboard designed to help dietitians deliver personalized remote dietary counseling in overweight adults (BMI ≥28 kg/m² at pharmacotherapy initiation) who had achieved ≥5% weight loss with GLP-1 RA therapy over 12-weeks. The PNA dashboard generated tailored nutritional recommendations to help participants achieve personalized weight loss goals based on an energy balance model that estimated daily caloric intake and nutritional quality using frequent body weight measurements, dietary logs, and physical activity data from a lifestyle-tracking app. To evaluate the PNA’s usability, we used a convergent parallel mixed-methods approach, combining a validated quantitative usability survey and qualitative focus-group interviews and feedback questionnaires with both dietitians and patients, alongside patient-reported satisfaction metrics for PNA-guided consultations (treatment satisfaction, general self-efficacy, and perceived health impact). Thematic analysis with a hybrid deductive-inductive methodology was applied to qualitative data, using 4 a priori themes derived from this study’s conceptual framework regarding prior expectations, perceived utility and satisfaction, usability challenges, and suggestions for clinical integration. Percent weight loss during the intervention was assessed as an exploratory outcome. Results: Among 78 participants (58/78, 74% women), on GLP-1 RA (mean weight loss of −13.3%, SD 6.7%, after 10, SD 5, months of treatment), between 3 and 5 remote nutrition consultations were delivered with PNA support. After the 3-month intervention period, weight loss was sustained in all participants (−0.2%, SD 2.5%), with 21% (16/78) suspending the GLP-1 RA due to drug shortages. Dietitians rated the PNA’s usability as moderate (62%) on the Healthcare Systems Usability Scale. Patients evaluated the perceived health impact of the PNA-assisted consultations at 19.1 (SD 3.5) of 25 on the user version of the Mobile Application Rating Scale. No significant differences were observed in patient-reported treatment satisfaction (=.78) or self-efficacy (=.57) before and after PNA-assisted care. Qualitative analysis identified convergence with quantitative findings across themes of usability, treatment satisfaction, and clinical integration, with divergence observed for self-efficacy and tracking motivation. Both patients and dietitians found the PNA valuable for generating actionable nutritional insights. Conclusions: While effective implementation of tools such as the PNA prototype demands dietitian training and workflow integration, they offer scalable, personalized nutrition or lifestyle guidance—as a therapeutic decision-support tool within weight loss interventions, with or without adjunct GLP-1 RA pharmacotherapy. Trial Registration: ClinicalTrials.gov NCT05997771; https://clinicaltrials.gov/study/NCT05997771
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/673e7709f46aa65c02e80d8ca5751306" />

Medtech CDMO Aptyx names new CEO

Aptyx has promoted CFO David Price to the role of CEO effective immediately, succeeding former Aptyx CEO Gregg Tobin. Price joined the Tempe, Arizona-based medical device contract development and manufacturing organization as CFO in 2025 and is “the right leader to build on Aptyx’s strong foundation and accelerate the company’s continued growth,” said John Pless,…

The post Medtech CDMO Aptyx names new CEO appeared first on Medical Design and Outsourcing.

AI is moving inside the device. Who owns the clinical risk?

Tips to mitigate the risk that medtech teams keep leaving unowned as artificial intelligence moves into Class II and III medical devices. By Dr. Sarah Matt, Vital Werks By the time a clinician trusts a wrong output from your artificial-intelligence-powered device, every decision that made the trust possible was made years earlier. How many decisions…

The post AI is moving inside the device. Who owns the clinical risk? appeared first on Medical Design and Outsourcing.